Immunovant, Inc.

NASDAQ:IMVT

Biotechnology

Healthcare
$33.17 +2.00%

+$0.69 today

Market cap
$6.86B
Beta
0.79
P/E (TTM)
-14.3
EPS (TTM)
-$2.48
52W Low $14.32High $36.29

Volume 0.91M

Average 1.84M

IMVT Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Immunovant, Inc.NASDAQ: IMVT

Cost of Revenue · Q2 FY2027 · quarter ended Sep 2026

Cost of revenue remains negative

Q2 FY2027 cost of revenue was $0, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $0.

Context

  • Cost of revenue increased in 0 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0— QoQ
Last fiscal yearMar 2026
$0— YoY
LTMSep 2026
$0— YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2026
0 USD
Year-over-year change
—

Cost of Revenue vs competitors

How IMVT compares with its peers on the latest reported figures

  • IMVT's LTM Sep 2026 cost of revenue of $0 is the 9th highest of the 11 companies compared; the peer median is $1.13M.
  • Cost of revenue amounts to 0.0% of revenue for IMVT, versus a peer median of 16.8%.
IMVT Competitors Peer median
Cost of Revenue for IMVT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TGTXTG Therapeutics, Inc.LTM Sep 2026$154.93M +98.5%+624.3%17.3%
TRAXFirst Tracks Biotherapeutics IncFY2025$139.61M -8.4%——
ZBIOZenas BioPharma, Inc.LTM Mar 2026$103.75M +54.1%——
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$1.98M -86.0%-44.1%23.7%
ANNXAnnexon, Inc.LTM Mar 2026$1.9M ———
QTTBQ32 Bio Inc.LTM Mar 2026$362K +0.6%-46.8%0.7%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$79K +2.6%——
IMUXImmunic, Inc.LTM Mar 2026$33K -50.0%——
IMVTImmunovant, Inc.LTM Sep 2026$0 ——0.0%
CABACabaletta Bio, Inc.LTM Mar 2026$0 ———
ANABAnaptysBio, Inc.LTM Mar 2026-$38.15M -122.7%-69.9%16.4%
Peer median (excluding IMVT) $1.13M-3.9%-45.4%16.8%

Competitors are the stored peer set for IMVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Mar 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development101.81M160.26M212.93M360.92M456.66M
Selling, General & Admin54.23M48.02M57.28M77.24M76.24M
Operating Expenses156.03M208.28M270.21M438.15M532.9M
Depreciation & Amortization126K193K231K377K409K
EBITDA(156.69M)(198.28M)(258.54M)(412.57M)(504.98M)
EBITDA Margin—————
Operating Income(156.03M)(208.28M)(270.21M)(438.15M)(532.9M)
Operating Margin—————
Interest Income07.58M24.95M24.73M25.33M
Interest Expense012.48M000
Other Income / Expenses(781K)(2.68M)11.44M25.2M27.51M
Income Before Tax(156.81M)(210.95M)(258.77M)(412.95M)(505.39M)
Pre-Tax Margin—————
Income Tax Expense(84K)9K567K891K215K
Net Income(156.73M)(210.96M)(259.34M)(413.84M)(505.61M)
Net Margin—————
EPS (Basic)(1.43)(1.71)(1.88)(2.73)(2.77)
EPS (Diluted)(1.43)(1.71)(1.88)(2.73)(2.77)
Weighted Avg Shares109.68M123.08M138.1M151.57M182.42M
Weighted Avg Shares (Diluted)109.68M123.08M138.1M151.57M182.42M

Immunovant, Inc.

NASDAQ:IMVT

Intrinsic Alpha fair value

Locked

Current Price

$33.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.